<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioaffinity Technologies, Inc. — News on 6ix</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc</link>
<description>Latest news and press releases for Bioaffinity Technologies, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 13:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioaffinity-technologies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354cf278dffbe2df0e5bcb.webp</url>
<title>Bioaffinity Technologies, Inc.</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc</link>
</image>
<item>
<title>bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-record-monthly-cypathr-lung-unit-sales-and-significant-year-over-year-growth-in-april-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-record-monthly-cypathr-lung-unit-sales-and-significant-year-over-year-growth-in-april-2026</guid>
<pubDate>Tue, 12 May 2026 13:15:00 GMT</pubDate>
<description>SAN ANTONIO, May 12, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath® Lung unit sales growth so far this year continues to exceed the Company’s internal projec</description>
</item>
<item>
<title>bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-first-quarter-2026-results-and-expanding-adoption-and-clinical-usage-of-cypathr-lung</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-first-quarter-2026-results-and-expanding-adoption-and-clinical-usage-of-cypathr-lung</guid>
<pubDate>Fri, 08 May 2026 12:30:00 GMT</pubDate>
<description>SAN ANTONIO, May 08, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026.</description>
</item>
<item>
<title>bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-launches-new-study-to-expand-use-of-cypathr-lung-technology-for-asthma-and-copd-diagnosis-and-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-launches-new-study-to-expand-use-of-cypathr-lung-technology-for-asthma-and-copd-diagnosis-and-treatment</guid>
<pubDate>Tue, 28 Apr 2026 13:16:00 GMT</pubDate>
<description>SAN ANTONIO, April 28, 2026--bioAffinity Technologies announces study with Brooke Army Medical Center to evaluate new diagnostic tests to improve treatment for asthma and COPD</description>
</item>
<item>
<title>bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-cypathr-lung-to-be-featured-at-cleveland-clinic-annual-advances-in-early-lung-cancer-detection-symposium-april-16</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-cypathr-lung-to-be-featured-at-cleveland-clinic-annual-advances-in-early-lung-cancer-detection-symposium-april-16</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity</description>
</item>
<item>
<title>bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-cypathr-lung-test-unit-sales-surged-146percent-year-over-year-in-q1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-cypathr-lung-test-unit-sales-surged-146percent-year-over-year-in-q1-2026</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and</description>
</item>
<item>
<title>bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-to-host-live-virtual-physician-roundtable-on-integrating-cypathr-lung-into-pulmonary-practice</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-to-host-live-virtual-physician-roundtable-on-integrating-cypathr-lung-into-pulmonary-practice</guid>
<pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
<description>SAN ANTONIO, March 25, 2026--bioAffinity Technologies will host a webinar on April 8 with leading pulmonologists who will share their clinical experience with CyPath Lung.</description>
</item>
<item>
<title>New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/new-case-study-bioaffinity-technologies-cypathr-lung-provides-actionable-results-and-helps-patient-avoid-costly-invasive-procedures</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/new-case-study-bioaffinity-technologies-cypathr-lung-provides-actionable-results-and-helps-patient-avoid-costly-invasive-procedures</guid>
<pubDate>Tue, 17 Mar 2026 11:45:00 GMT</pubDate>
<description>SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome.</description>
</item>
<item>
<title>bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-record-2025-revenue-and-unit-sales-for-flagship-lung-cancer-diagnostic-cypathr-lung-112</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-record-2025-revenue-and-unit-sales-for-flagship-lung-cancer-diagnostic-cypathr-lung-112</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number of</description>
</item>
<item>
<title>bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypathr-lung-cancer-diagnostic-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypathr-lung-cancer-diagnostic-1</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at</description>
</item>
<item>
<title>bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-presents-positive-research-findings-for-its-novel-diagnostic-platform-technology-to-identify-optimal-therapies-for-asthma-patients</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-presents-positive-research-findings-for-its-novel-diagnostic-platform-technology-to-identify-optimal-therapies-for-asthma-patients</guid>
<pubDate>Tue, 03 Mar 2026 13:30:00 GMT</pubDate>
<description>SAN ANTONIO, March 03, 2026--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies</description>
</item>
<item>
<title>bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-validation-study-with-brooke-army-medical-center-to-expand-sample-collection-options-for-the-cypathr-lung-noninvasive-early-detection-lung-cancer-test</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-validation-study-with-brooke-army-medical-center-to-expand-sample-collection-options-for-the-cypathr-lung-noninvasive-early-detection-lung-cancer-test</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>SAN ANTONIO, February 25, 2026--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.</description>
</item>
<item>
<title>New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/new-case-study-highlights-ability-of-bioaffinity-technologies-cypathr-lung-to-reduce-diagnostic-burden-for-patients-at-risk-for-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/new-case-study-highlights-ability-of-bioaffinity-technologies-cypathr-lung-to-reduce-diagnostic-burden-for-patients-at-risk-for-lung-cancer</guid>
<pubDate>Thu, 19 Feb 2026 16:00:00 GMT</pubDate>
<description>SAN ANTONIO, Texas, February 19, 2026--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.</description>
</item>
<item>
<title>Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/clinical-utility-bioaffinity-technologies-cypath-130000107</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/clinical-utility-bioaffinity-technologies-cypath-130000107</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN ANTONIO, Texas, February 17, 2026--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.</description>
</item>
<item>
<title>bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-appoints-nationally-recognized-130000121</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-appoints-nationally-recognized-130000121</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN ANTONIO, February 09, 2026--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board</description>
</item>
<item>
<title>bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-laboratory-maintains-prestigious-130000055</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-laboratory-maintains-prestigious-130000055</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>SAN ANTONIO, January 07, 2026--bioAffinity's laboratory, Precision Pathology Laboratory Services, maintains accreditation from the College of American Pathologists</description>
</item>
<item>
<title>bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-noninvasive-cypath-lung-130000149</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-noninvasive-cypath-lung-130000149</guid>
<pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
<description>SAN ANTONIO, Texas, December 03, 2025--bioAffinity Technologies will present case studies at NLCRT in which CyPath® Lung identified Stage 1A lung cancer in high-risk patients.</description>
</item>
<item>
<title>bioAffinity Technologies Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-third-quarter-130000001</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-third-quarter-130000001</guid>
<pubDate>Fri, 14 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN ANTONIO, November 14, 2025--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue.</description>
</item>
<item>
<title>bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-accelerating-month-130000384</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-reports-accelerating-month-130000384</guid>
<pubDate>Wed, 05 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN ANTONIO, November 05, 2025--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October increased by 111% over the 2025 monthly average.</description>
</item>
<item>
<title>bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-acceptance-australian-120000838</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-announces-acceptance-australian-120000838</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN ANTONIO, October 28, 2025--Australian Patent Office accepts bioAffinity Technologies' patent application for its platform technology to assess lung health and predict disease.</description>
</item>
<item>
<title>bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025</title>
<link>https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-presents-research-supporting-120000891</link>
<guid isPermaLink="true">https://6ix.com/company/bioaffinity-technologies-inc/news/bioaffinity-technologies-presents-research-supporting-120000891</guid>
<pubDate>Mon, 20 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN ANTONIO, October 20, 2025--bioAffinity Technologies will present research related to its noninvasive CyPath Lung test for lung cancer at CHEST 2025.</description>
</item>
</channel>
</rss>